| Company/Division name | Eli Lilly and Company |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2023 |
| Capital investment ($): | 470 |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | diabetes drugs for Type 2 diabetes |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market |
